

Special Issue

Drug Targets for Head and Neck Cancer

Message from the Guest Editors

The term head and neck cancers refers to variations of the disease that usually begin in the squamous cells that line the mucosal epithelium of the upper aerodigestive tract and also includes the cutaneous malignancies of the head and neck region, as well as malignant tumors arising from different cell types of the thyroid and salivary glands. It constitutes the sixth most common malignancy in the world and, in recent years, the incidence of this cancer is slowly and consistently increasing. The overall 5-year survival rate for head and neck cancers is approximately 50%. Thus, its treatment remains one of the major challenges of modern medicine. This Special Issue welcomes research articles and review papers focused on pathogenetic, chemoresistance, drug targets molecular biology and therapeutic perspectives in head and neck cancer from basic translational science studies to clinical research. All authors are invited to send their research related to the topic of our Special Issue, both original and review articles, to be assessed and included in the peer review process of our journal.

Guest Editors

Prof. Dr. Mu-Kuan Chen

Department of Otorhinolaryngology, Head and Neck Surgery, Changhua Christian Hospital, Changhua 500, Taiwan

Dr. Ming-Ju Hsieh

Oral Cancer Research Center, Changhua Christian Hospital, Changhua 500, Taiwan

Deadline for manuscript submissions

closed (31 July 2023)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/156165

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)